AmpliPhi Biosciences

OverviewSuggest Edit

AmpliPhi Biosciences Corporation is a biotechnology company that focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The Company is working on products for the treatment of Staphylococcus aureus and pseudomonas aeruginosa lung infections. AmpliPhi Biosciences Corporation has research, license and collaboration agreements with a number of institutes.
StateClosed
TypePublic
Founded1989
HQSan Diego, US
Websiteampliphibio.com

Latest Updates

Employees (est.) (Mar 2019)30(-3%)
Revenue (FY, 2014)$409 K
Share Price (May 2019)$0.3 (-20%)

Key People/Management at AmpliPhi Biosciences

Paul Grint

Paul Grint

CEO
Steve Martin

Steve Martin

CFO
Igor Bilinsky

Igor Bilinsky

COO
Sandra Morales

Sandra Morales

Vice President of Research
Alexander Gaidamaka

Alexander Gaidamaka

Vice President of Chemistry, Manufacturing and Controls
Carrie-Lynn Langlais Furr

Carrie-Lynn Langlais Furr

Vice President of Regulatory Affairs and Program Management
Show more

AmpliPhi Biosciences Office Locations

AmpliPhi Biosciences has offices in San Diego, Richmond, Brookvale and Ljubljana
San Diego, US (HQ)
3579 Valley Centre Dr # 300
Richmond, US
Biotech Center, 800 E Leigh St
Brookvale, AU
27 Dale St
Ljubljana, SI
259 Litijska cesta
Show all (4)

AmpliPhi Biosciences Financials and Metrics

AmpliPhi Biosciences Revenue

AmpliPhi Biosciences's revenue was reported to be $409 k in FY, 2014
USD

Net income (Q1, 2020)

(5.1m)

Market capitalization (9-May-2019)

10.6m

Closing stock price (9-May-2019)

0.3

Cash (31-Mar-2020)

24.2m

EV

(11.0m)
AmpliPhi Biosciences's current market capitalization is $10.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

409.0k

Revenue growth, %

16%(45%)

General and administrative expense

6.9m6.4m8.4m7.6m5.7m9.3m

R&D expense

5.8m4.0m5.7m2.9m4.9m9.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

101.0k103.0k102.0k

General and administrative expense

1.6m2.0m1.7m1.4m1.6m1.6m2.6m2.5m1.8m1.9m2.8m1.6m1.6m1.4m1.3m2.1m2.1m3.8m2.2m

R&D expense

1.0m1.9m1.8m972.0k1.1m728.0k2.0m1.2m1.7m1.5m1.1m1.5m1.7m361.0k1.5m3.1m3.0m2.8m

Operating expense total

2.6m3.8m3.5m2.4m2.7m2.3m4.6m3.7m3.4m3.4m3.9m1.6m3.1m3.1m1.6m3.6m5.2m6.8m4.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.6m9.4m5.7m5.1m8.2m6.0m

Accounts Receivable

100.0k125.0k25.0k

Prepaid Expenses

339.0k521.0k253.0k251.0k622.0k

Current Assets

7.0m10.0m6.4m5.4m8.4m6.7m
Quarterly
USDY, 2020

EV/CFO

2.6 x

Financial Leverage

1.3 x
Show all financial metrics

AmpliPhi Biosciences Online and Social Media Presence

Embed Graph

AmpliPhi Biosciences News and Updates

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the...

Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

NEW YORK, April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of APHB to C3J Therapeutics, Inc. If you are a APHB investor, and would like additional...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHB

NEW YORK, March 27, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of AmpliPhi Biosciences Corporation...

Bacteriophage market size, share and Forecast 2026: Leading players AmpliPhi Biosciences Corporation, EnBiotix, Phage Biotech Ltd., Fixed-Phage Limited, InnoPhage, Pherecydes Pharma Company

The global bacteriophage market held US$ 567.9 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 3.9% during the forecast period from 2018 to 2026. Bacteriophages are estimated as the most widely distributed and varied entities in the biosphere. Posted via Industry Today. Foll…

AmpliPhi Biosciences Blogs

Research Associate I R&D/PD

Armata Pharmaceuticals is a clinical-stage biotechnology company advancing the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Position Objective: The Research Associate I position will support the research and development effort…

Research Associate I Research & Development

Armata Pharmaceuticals is a clinical-stage biotechnology company advancing the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Position Objective: The Research Associate I position will support the research and development effort…

Research Associate I Process Development

Armata Pharmaceuticals is a clinical-stage biotechnology company advancing the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Position Objective: The Research Associate I position will support process development by assisting in…

Research Associate I DNA Sequencing and Genetic Engineering

Armata Pharmaceuticals is a clinical-stage biotechnology company advancing the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Position Objective: The Research Associate I position will be integrated to the discovery and biologic…
Show more

AmpliPhi Biosciences Frequently Asked Questions

  • When was AmpliPhi Biosciences founded?

    AmpliPhi Biosciences was founded in 1989.

  • Who are AmpliPhi Biosciences key executives?

    AmpliPhi Biosciences's key executives are Paul Grint, Steve Martin and Igor Bilinsky.

  • How many employees does AmpliPhi Biosciences have?

    AmpliPhi Biosciences has 30 employees.

  • Who are AmpliPhi Biosciences competitors?

    Competitors of AmpliPhi Biosciences include Acousia Therapeutics, Prevail Therapeutics and BioSpecifics Technologies.

  • Where is AmpliPhi Biosciences headquarters?

    AmpliPhi Biosciences headquarters is located at 3579 Valley Centre Dr # 300, San Diego.

  • Where are AmpliPhi Biosciences offices?

    AmpliPhi Biosciences has offices in San Diego, Richmond, Brookvale and Ljubljana.

  • How many offices does AmpliPhi Biosciences have?

    AmpliPhi Biosciences has 4 offices.